Department of Radiation Oncology, Korea University Guro Hospital, 97 Gurodong-Gil Guro-Ku, Seoul, Korea.
Breast Cancer Res Treat. 2011 Feb;125(3):849-53. doi: 10.1007/s10549-010-1070-1. Epub 2010 Jul 21.
Published studies on the association between the vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism and breast cancer risk are inconclusive, and a meta-analysis is required to verify the association. Nine studies, including a total of 4,973 cases and 5,035 controls, were subjected to meta-analysis. When all eligible subjects were pooled for meta-analysis, the CT + TT genotypes were not associated with a significant decrease in breast cancer risk (odds ratio = 0.87; 95% confidence interval 0.75-1.02; P = 0.087). We also categorized by ethnicity (Caucasian, Asian, or mixed) for subgroup analysis, however, according to this subgroup analysis, we found no significant association between the CT and TT versus CC genotype with breast cancer risk reduction in any of the subgroups. We conclude that the VEGF gene 936 C/T polymorphism does not affect breast cancer risk.
已发表的关于血管内皮生长因子 (VEGF) 基因 936 C/T 多态性与乳腺癌风险之间关联的研究结果并不一致,需要进行荟萃分析来验证这种关联。共纳入了 9 项研究,总计 4973 例病例和 5035 例对照,对这些研究进行了荟萃分析。当汇总所有合格的受试者进行荟萃分析时,CT + TT 基因型与乳腺癌风险降低无关(比值比=0.87;95%置信区间 0.75-1.02;P=0.087)。我们还按种族(白种人、亚洲人或混合人群)进行了亚组分析,但根据该亚组分析,我们没有发现 CT 和 TT 与 CC 基因型与乳腺癌风险降低之间存在任何显著关联。我们得出结论,VEGF 基因 936 C/T 多态性不会影响乳腺癌风险。